Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Acta Med Iran ; 55(8): 482-485, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-29034643

RESUMO

 Behçet's disease is a chronic, recurrent, inflammatory disorder characterized by orogenital ulcers and skin lesions; serious manifestations also include ocular, large vessel, gastrointestinal and neurological involvement. Genetic and unknown environmental factors modify the wide clinical spectrum of the disease. During the long clinical course of the disease, testicular and epididymal involvement has been reported, with scrotal pain and swelling being the most common symptoms. In this review, we discuss the various aspects of epididymo-orchitis in Behcet's disease patients, and we evaluate the diagnostic approaches as well as the empirical therapeutic modalities of this entity.


Assuntos
Síndrome de Behçet/complicações , Epididimite/etiologia , Orquite/etiologia , Humanos , Masculino
2.
Case Rep Med ; 2015: 414102, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26351459

RESUMO

Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease, which affects a wide variety of organs including the spleen. Splenic involvement in SLE includes conditions such as splenomegaly, hyposplenism, infarction, and spontaneous rupture. However, only a few cases of splenic calcifications in patients with SLE have been reported. Herein, we present a case of a 24-year-old female diagnosed with SLE, in which we found diffuse splenic calcifications. The unique pattern of splenic calcifications in SLE contributes to the differential diagnosis from other conditions such as infections and other connective tissue diseases, which also cause calcifications in the spleen.

3.
Clin Exp Rheumatol ; 32(4 Suppl 84): S140-8, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25268668

RESUMO

Behçet's disease is a chronic, recurrent, inflammatory disorder characterized by orogenital ulcers and skin lesions; serious manifestations also include ocular, large vessel, gastrointestinal and neurological involvement. Genetic and unknown environmental factors customise the wide clinical expression of the disease. Gastrointestinal involvement is not unusual, albeit with a highly variable frequency among different ethnic populations. However, given the fact that gastrointestinal symptoms such as reflux, bleeding, diarrhoea are common in the general population, their clinical significance needs to be carefully interpreted. Apart from mouth the ileocecal area is typically involved, but inflammatory and/or vasculitic lesions may affect any part of the gastrointestinal tract. Complications such as perforation carry high morbidity rates and even mortality. Herein, we review all available information pertinent to gastrointestinal involvement of Behçet's disease and discuss the published advances in evaluation and its empirical management, including anti-TNF biologic therapies.


Assuntos
Síndrome de Behçet , Gastroenteropatias , Trato Gastrointestinal/patologia , Síndrome de Behçet/complicações , Síndrome de Behçet/diagnóstico , Síndrome de Behçet/terapia , Gastroenteropatias/diagnóstico , Gastroenteropatias/etiologia , Gastroenteropatias/terapia , Humanos
4.
Rheumatology (Oxford) ; 50(3): 593-7, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21097877

RESUMO

OBJECTIVE: To compare a single infusion of the anti-TNF antibody infliximab vs CSs for acute panuveitis attacks in Behçet's disease (BD). METHODS: A prospective, observational study of patients with panuveitis, who received either an infliximab infusion (5 mg/kg, 19 eyes) or high-dose methylprednisolone intravenously (1 g/day for 3 days, 8 eyes), or intra-vitreal triamcinolone acetonide (4 mg, 8 eyes) at attack's onset. Baseline maintenance therapy remained unchanged during the following 30 days. Visual acuity, anterior chamber cells, vitreous cells and inflammation of the posterior eye segment were assessed at baseline and at Days 1, 7, 14 and 29 (±1) post-treatment. RESULTS: While no significant differences were noted between i.v. and intra-vitreal CSs, infliximab was faster than CSs in decreasing total ocular inflammation scores and fundus inflammation scores (P = 0.01 and P < 0.0001 for treatment × time(2) interaction, respectively, using generalized estimating equation analysis). Independently of time, infliximab was superior to CSs in clearing retinal vasculitis (P < 0.003), as well as in resolution of retinitis (P = 0.008) and cystoid macular oedema (P < 0.007). Moreover, a faster regression of cystoid macular oedema was observed with infliximab compared with CSs (P < 0.03). The beneficial effects of the three treatment modalities on visual acuity were comparable from baseline to the end of follow-up. No side effects were noted with infliximab or methylprednisolone, whereas intra-vitreal triamcinolone acetonide caused ocular hypertension in four of the eight eyes, requiring surgical intervention in two. CONCLUSION: A single infusion of infliximab should always be considered, even as an adjunct therapy, for the control of acute panuveitis attacks in BD.


Assuntos
Anti-Inflamatórios/administração & dosagem , Anticorpos Monoclonais/administração & dosagem , Síndrome de Behçet/tratamento farmacológico , Metilprednisolona/administração & dosagem , Triancinolona/administração & dosagem , Uveíte/tratamento farmacológico , Adulto , Síndrome de Behçet/complicações , Feminino , Humanos , Infliximab , Infusões Intravenosas , Injeções Intravítreas , Masculino , Resultado do Tratamento , Uveíte/etiologia , Adulto Jovem
5.
Nat Genet ; 42(8): 698-702, 2010 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20622878

RESUMO

Behçet's disease is a genetically complex disease of unknown etiology characterized by recurrent inflammatory attacks affecting the orogenital mucosa, eyes and skin. We performed a genome-wide association study with 311,459 SNPs in 1,215 individuals with Behçet's disease (cases) and 1,278 healthy controls from Turkey. We confirmed the known association of Behçet's disease with HLA-B*51 and identified a second, independent association within the MHC Class I region. We also identified an association at IL10 (rs1518111, P = 1.88 x 10(-8)). Using a meta-analysis with an additional five cohorts from Turkey, the Middle East, Europe and Asia, comprising a total of 2,430 cases and 2,660 controls, we identified associations at IL10 (rs1518111, P = 3.54 x 10(-18), odds ratio = 1.45, 95% CI 1.34-1.58) and the IL23R-IL12RB2 locus (rs924080, P = 6.69 x 10(-9), OR = 1.28, 95% CI 1.18-1.39). The disease-associated IL10 variant (the rs1518111 A allele) was associated with diminished mRNA expression and low protein production.


Assuntos
Síndrome de Behçet/genética , Genes MHC Classe I/genética , Estudo de Associação Genômica Ampla , Interleucina-10/genética , Alelos , Ásia , Síndrome de Behçet/imunologia , Estudos de Casos e Controles , Europa (Continente) , Antígenos HLA-B/genética , Antígenos HLA-B/imunologia , Humanos , Interleucina-10/imunologia , Oriente Médio , Polimorfismo de Nucleotídeo Único , Turquia
6.
Clin Rheumatol ; 29(11): 1211-6, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20495938

RESUMO

Behçet's disease (BD) is a chronic multisystemic inflammatory disorder of unknown origin consisting of oral aphthous ulcers, ocular symptoms, skin lesions, and genital ulcerations. It has many features in common with systemic vasculitides and is more prevalent in countries along the ancient Silk route. Immune-mediated mechanisms play a major role in the pathogenesis of the disease, and inflammatory mediators are also involved. BD is not considered to be an autoimmune disorder, and the character of the disease needs to be clarified. Immunological aberrations in BD have been extensively studied by many investigators; genetic factors have been related to disease susceptibility, but their exact role in the development of disease is uncertain. Environmental factors such as infectious agents have also been implicated in the etiology of BD. However, the etiopathogenesis of the disease remains to be elucidated. Factors involved in the immunopathogenesis of BD with emphasis on the role of immunological aberrations are analyzed in this review.


Assuntos
Síndrome de Behçet/etiologia , Síndrome de Behçet/imunologia , Autoanticorpos/química , Síndrome de Behçet/genética , Síndrome de Behçet/fisiopatologia , Endotélio/metabolismo , Meio Ambiente , Feminino , Predisposição Genética para Doença , Proteínas de Choque Térmico/metabolismo , Helicobacter pylori/metabolismo , Humanos , Sistema Imunitário , Inflamação , Masculino , Neutrófilos/metabolismo , Linfócitos T/metabolismo , Trombofilia/imunologia , Trombofilia/metabolismo
7.
Curr Rheumatol Rep ; 10(5): 349-55, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18817637

RESUMO

Behçet's disease (BD) is a chronic, multisystem, inflammatory disorder that is classified among the systemic vasculitidies. Its cause has yet to be determined, but genetic and environmental factors and immune dysregulation are thought to play a role in its pathogenesis. The diagnosis of the disease and recognition and separation from disorders that may mimic BD may be difficult, especially in areas where the disease is uncommon. Certainty as to the best treatments for the various manifestations of BD is often unclear due to limited randomized controlled trials. However, existing consensus statements and expert opinions should help to guide therapy. This review examines important recent contributions to help the clinician more readily recognize patients with the disease and institute appropriate care.


Assuntos
Azatioprina/uso terapêutico , Síndrome de Behçet/diagnóstico , Síndrome de Behçet/tratamento farmacológico , Glucocorticoides/uso terapêutico , Imunossupressores/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Síndrome de Behçet/complicações , Quimioterapia Combinada , Diagnóstico Precoce , Humanos , Infliximab , Cooperação Internacional , Guias de Prática Clínica como Assunto , Ensaios Clínicos Controlados Aleatórios como Assunto , Sociedades Médicas , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Fator de Necrose Tumoral alfa/imunologia
8.
J Card Fail ; 12(6): 458-63, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16911913

RESUMO

BACKGROUND: Adamantiades-Behçet's disease (ABD) is characterized by systemic vasculitis. We investigated whether aortic distensibility and arterial wave reflections are linked to left ventricular (LV) diastolic dysfunction in ABD. METHODS AND RESULTS: Eighty-two patients and 40 controls with similar atherosclerotic risk factors were examined by applanation tonometry of the radial artery (SphygmoCor) and echocardiography. Augmentation index (AI%) and arrival time (Deltat, ms) of reflected arterial waves as well as aortic distensibility (AoD) assessed by echocardiography were estimated. Doppler diastolic abnormalities were defined as proposed by the European Study Group on Diastolic Heart Failure by measurement of E/A ratio, isovolumic relaxation time, deceleration time, and flow propagation velocity. Patients had impaired central augmentation index (CAI), Deltat, and AoD compared with controls (P > .05). After adjusting for age, atherosclerotic risk factors, left ventricular mass, and medication the odds-ratio of AoD and CAI for left ventricular diastolic dysfunction was 0.664 (95%CI 0.449-0.982), P = .04, and 1.073 (95% CI 1.014-1.140), P = .001, respectively. The addition of CAI to the multivariable model including AoD significantly increased the power of the model for prediction of left ventricular diastolic dysfunction (-2 Log likelihood change = 18.8, P for change > .01). CONCLUSION: Augmentation index has a complementary value to aortic distensibility in the assessment of left ventricular diastolic dysfunction in ABD.


Assuntos
Artérias/fisiopatologia , Síndrome de Behçet/complicações , Pressão Sanguínea , Pulso Arterial , Disfunção Ventricular Esquerda/etiologia , Disfunção Ventricular Esquerda/fisiopatologia , Adulto , Aorta Torácica/fisiopatologia , Complacência (Medida de Distensibilidade) , Diástole , Ecocardiografia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Cardiovasculares , Valor Preditivo dos Testes , Artéria Radial/fisiopatologia , Vasodilatação , Disfunção Ventricular Esquerda/diagnóstico por imagem
9.
J Am Coll Cardiol ; 43(6): 1075-81, 2004 Mar 17.
Artigo em Inglês | MEDLINE | ID: mdl-15028369

RESUMO

OBJECTIVES: We investigated whether Adamantiades-Behcet's disease (ABD) is related to impaired aortic (Ao) elastic properties and left ventricular (LV) function. BACKGROUND: Adamantiades-Behcet's disease is an inflammatory disorder characterized by vasculitis leading to vascular complications and, rarely, myocarditis. METHODS: We studied 82 patients with ABD (age: 40 +/- 12 years) and 24 normal control subjects by echocardiography. Abdominal Ao diameter (mm/m(2)) and Ao elastic indexes--namely, Ao strain (%), distensibility (cm(2) x dyn(-1)x 10(-6)), stiffness index, and pressure strain modulus (Ep) (cm(2) x dyn(-1) x 10(-6))--were calculated from the echocardiographically derived thoracic Ao diameters (mm/m(2)), and the measurement of pulse pressure obtained by cuff sphygmomanometry. Isovolumic relaxation time (IVRT) (ms), deceleration time (DT) (ms), and flow propagation velocity (FPV) (cm/s) were measured by Doppler echocardiography to assess diastolic LV function. The duration of disease and presence of vascular complications were noted. RESULTS: Patients versus control subjects had increased Ao diameters (p < 0.01), lower mean Ao strain and distensibility (4 vs. 9 and 1.4 vs. 3.4, respectively, p < 0.01), higher mean aortic stiffness index and Ep (15.6 vs. 6 and 1.17 vs. 0.44, respectively, p < 0.01), and impaired IVRT and FPV (p < 0.01). Aortic function indexes were related to the duration of disease (p < 0.01) and increased DT (p < 0.01). Deceleration time >190 ms predicted vascular complications with 80% sensitivity and 71% specificity (odds ratio 6.52 [confidence interval: 2.23 to 19.03]). CONCLUSION: Aortic elastic properties and diastolic LV function are impaired in patients with ABD and are interrelated. The link between diastolic LV dysfunction and vascular complications suggests the presence of a common pathophysiologic pathway and provides a possible marker of risk for vascular disease.


Assuntos
Aorta Torácica/fisiopatologia , Arteriosclerose/fisiopatologia , Síndrome de Behçet/fisiopatologia , Disfunção Ventricular Esquerda/fisiopatologia , Adulto , Idoso , Aorta Torácica/diagnóstico por imagem , Arteriosclerose/diagnóstico por imagem , Estudos de Casos e Controles , Diástole , Ecocardiografia Doppler/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Estudos Prospectivos , Índice de Gravidade de Doença , Disfunção Ventricular Esquerda/diagnóstico por imagem , Disfunção Ventricular Esquerda/patologia
13.
Leuk Lymphoma ; 44(5): 893-4, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12802935

RESUMO

A case of systemic lupus erythematosus (SLE) complicated by multiple myeloma is presented; the lupus diagnosis was put together with the diagnosis of myeloma but the symptoms had commenced a few years before. The putative mechanisms underlying this unusual combination are discussed.


Assuntos
Lúpus Eritematoso Sistêmico/complicações , Mieloma Múltiplo/complicações , Idoso , Feminino , Humanos , Lúpus Eritematoso Sistêmico/diagnóstico , Mieloma Múltiplo/diagnóstico , Paraproteinemias
14.
Leuk Lymphoma ; 44(2): 373-4, 2003 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-12688362

RESUMO

A case of systemic lupus erythematosus (SLE) complicated by multiple myeloma is presented. The lupus diagnosis was established together with the diagnosis of myeloma but the symptoms had commenced a few years before. The putative mechanisms underlying this unusual combination are discussed.


Assuntos
Lúpus Eritematoso Sistêmico/complicações , Mieloma Múltiplo/complicações , Idoso , Cloroquina/uso terapêutico , Feminino , Humanos , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Melfalan/uso terapêutico , Mieloma Múltiplo/diagnóstico , Mieloma Múltiplo/tratamento farmacológico , Paraproteinemias , Prednisona/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA